加载中
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$18.585
−US$0.095 · -0.51%
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
常规交易时段
US$18.585
−US$0.095 · -0.51%
盘中时间采用ET。市场数据可能有所延迟。
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
日内区间
当前US$18.585
52周区间
当前US$18.585
盘中时间采用ET。市场数据可能有所延迟。
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
日内区间
当前US$18.585
52周区间
当前US$18.585
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（JPY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.78万亿 JPY | 4.58万亿 JPY | 4.26万亿 JPY | 4.03万亿 JPY | 3.57万亿 JPY |
| 销货成本 | 2.34万亿 JPY | 1.58万亿 JPY | 1.43万亿 JPY | 1.24万亿 JPY | 1.11万亿 JPY |
| 毛利 | 2.44万亿 JPY | 3万亿 JPY | 2.83万亿 JPY | 2.78万亿 JPY | 2.46万亿 JPY |
| 研究与开发 | 7166.88亿 JPY | 7302.27亿 JPY | 7299.24亿 JPY | 6333.25亿 JPY | 5260.87亿 JPY |
| 销售、一般及管理费用 | 1.15万亿 JPY | 1.1万亿 JPY | 1.05万亿 JPY | 9973.09亿 JPY | 8863.61亿 JPY |
| 营业费用 | 1.87万亿 JPY | 2.66万亿 JPY | 2.62万亿 JPY | 2.29万亿 JPY | 2万亿 JPY |
| 利息收入 | 2239.13亿 JPY | 196.38亿 JPY | 7809.7万 JPY | 55.08亿 JPY | 45.91亿 JPY |
| 利息支出 | 3791.36亿 JPY | 1373.11亿 JPY | 10.62亿 JPY | 1169.73亿 JPY | 1224.32亿 JPY |
| 折旧和摊销 | 7211.27亿 JPY | 7613.96亿 JPY | 7280.02亿 JPY | 6644亿 JPY | 5831.51亿 JPY |
| 营业利润 | 5730.42亿 JPY | 3425.86亿 JPY | 2140.75亿 JPY | 4905.05亿 JPY | 4608.44亿 JPY |
| 净利润 | 2033.27亿 JPY | 1079.28亿 JPY | 1440.67亿 JPY | 3170.17亿 JPY | 2300.59亿 JPY |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
First Trust Value Line Dividend Index FundFVD3189.73万0.42%76.22亿 USD0.62%US$48.01+0.08%
VanEck Pharmaceutical ETFPPH2882.45万2.76%10.45亿 USD0.36%US$109.78-0.84%
Avantis International Equity ETFAVDE1050.79万0.05%192.5亿 USD0.23%US$89.825+0.27%
ActivePassive International Equity ETFAPIE283.43万0.25%11.36亿 USD0.45%US$38.545+0.38%
Vanguard FTSE All-World ex-US ETFVEU221.83万0.00%986亿 USD0.04%US$82.375-0.14%
iShares Dynamic Equity Active ETFBDYN145.39万0.05%31.59亿 USD0.40%US$27.96-0.29%
Adasina Social Justice All Cap Global ETFJSTC110.99万0.37%3.01亿 USD0.89%US$22.635-0.51%
iShares Flexible Equity Active ETFBFLX90.18万0.04%21.85亿 USD0.40%US$25.911-0.59%First Trust Value Line Dividend Index FundFVDVanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEActivePassive International Equity ETFAPIEVanguard FTSE All-World ex-US ETFVEUiShares Dynamic Equity Active ETFBDYNAdasina Social Justice All Cap Global ETFJSTCiShares Flexible Equity Active ETFBFLXAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
